Clark’s stock continued for a second day and raised the prospect that an activist investor could surface and try to block its merger-of-equals deal with Tylenol maker Kenvue.
On the losing end of Wall Street Monday was Kimberly-Clark, which dropped 14.6% after it said it would buy Kenvue in a deal valuing it at $48.7 billion. Kenvue, which sells Tylenol, Band-Aids and ...
Kash Patel drama, and restarting nuclear tests. Nov. 4, 2025 – 02:01 – GOP leaders downplay chances as Democrats expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback